Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
3.830
+0.090 (2.41%)
At close: Nov 28, 2025, 1:00 PM EST
3.870
+0.040 (1.04%)
After-hours: Nov 28, 2025, 4:50 PM EST
Precigen Revenue
Precigen had revenue of $2.92M in the quarter ending September 30, 2025, with 206.61% growth. This brings the company's revenue in the last twelve months to $6.31M, up 59.20% year-over-year. In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%.
Revenue (ttm)
$6.31M
Revenue Growth
+59.20%
P/S Ratio
180.73
Revenue / Employee
$44,119
Employees
143
Market Cap
1.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
| Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PGEN News
- 3 days ago - Precigen Is Still A Buy After The Papzimeos Rally - Seeking Alpha
- 15 days ago - Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PRNewsWire
- 22 days ago - Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 - PRNewsWire
- 27 days ago - Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares - The Motley Fool
- 6 weeks ago - Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 2 months ago - These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - The Motley Fool
- 3 months ago - Precigen Announces Up to $125 Million Non-Dilutive Financing - PRNewsWire